ClinicalTrials.gov
ClinicalTrials.gov Menu

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03283228
Recruitment Status : Not yet recruiting
First Posted : September 14, 2017
Last Update Posted : September 14, 2017
Sponsor:
Information provided by (Responsible Party):
Z A Kamel, Assiut University

Brief Summary:
  1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
  2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Condition or disease Intervention/treatment
Adult Acute Myeloid Leukemia Diagnostic Test: Cd11b and Cd56 markers

Detailed Description:
  1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
  2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Estimated Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : October 1, 2019


Group/Cohort Intervention/treatment
CD11b and CD56 markers
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Diagnostic Test: Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Name: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Haematological parameters in cases of adult AML
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
Diagnostic Test: Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Name: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia




Primary Outcome Measures :
  1. CD11b and CD56 marker [ Time Frame: 24 month ]
    Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Anew diagnosis cases of adult AML
Criteria

Inclusion Criteria:

Anew diagnosis cases of adult AML

Exclusion Criteria:

  1. Pediatric AML .
  2. follow up cases of adult AML

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03283228


Contacts
Contact: Shaaban Helal, PHD 01005688567 Elhelal2007@gmail.com
Contact: Eman Salah Eldin, lecture 01028030966 Emansalah.eldin@yahoo.com

Sponsors and Collaborators
Assiut University

Responsible Party: Z A Kamel, Dr, Assiut University
ClinicalTrials.gov Identifier: NCT03283228     History of Changes
Other Study ID Numbers: Myeloid Leukemia Markers
First Posted: September 14, 2017    Key Record Dates
Last Update Posted: September 14, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms